Recurrent Gastric Cancer Terminated Phase 1 Trials for Trastuzumab (DB00072)

Also known as: Gastric cancer recurrent / Stomach cancer recurrent / Stomach carcinoma recurrent / Gastric carcinoma recurrent

IndicationStatusPhase
DBCOND0028800 (Recurrent Gastric Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01705340Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTreatment